What is the 13F Pro Quality Score for TWST?

13F Pro ranks Twist Bioscience Corp (TWST) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TWST's current score at https://13fpro.ai/research/TWST (free sign-up required for the full ranking).

Where does 13F Pro source TWST data?

All Twist Bioscience Corp fundamentals and ownership data come directly from SEC EDGAR. Twist Bioscience Corp files with the SEC under CIK 1581280. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TWST in?

Twist Bioscience Corp (TWST) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is TWST research updated on 13F Pro?

TWST's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Twist Bioscience Corp(TWST)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1581280 TWST stock profile & AI dashboard →

13F Pro Quality Score

33.3/100

Rank #2,237 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

80.3/100

Profitability

17.4/100

Balance Sheet

14.0/100

Earnings Quality

30.0/100

Free Cash Flow

13.5/100

Institutional Flow

51.5/100

Revenue Scale

33.6/100

Dilution Risk

11.0/100

TWST Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Twist Bioscience Corp (TWST), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TWST at 33.3/100 on a 32-signal composite quality model, placing it at rank #2,237 of 2,879 stocks — the bottom half of the AI-ranked universe. TWST scores in the top quartile across revenue growth (80.3). Areas of concern include free cash flow (13.5) and balance sheet strength (14.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 11.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Twist Bioscience Corp reports quarterly revenue of $110.7M, net income of $-44.0M, an operating margin of -41.4%. Top institutional holders of TWST by reported 13-F value include Artisan Partners Limited Partnership, ARK Investment Management, BlackRock,, based on the most recent SEC filings. TWST trades on the Nasdaq exchange and files with the SEC under CIK 1581280. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TWST daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Twist Bioscience Corp directly from SEC EDGAR. Twist Bioscience Corp's 13F Pro composite quality score has ranged between 8 and 68 since 2023, currently 33.3 — an improving long-term trajectory across 43 quarterly and live scoring snapshots.

✦

Fun facts about Twist Bioscience Corp

Quirks, history, and lore behind TWST — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap life-sciences company headquartered in South San Francisco · listed on Nasdaq · operating in the synthetic biology space.
2
The Numbers
Annual revenue in the range of roughly $200 million, with the company still burning cash as it scales — classic pre-profitability biotech math.
3
The History
Founded around 2013 and spun out of research at UC San Francisco, it went public in 2018 with a mission to make writing DNA as routine as printing a document.
4
The Secret
Its secret weapon is a silicon-based DNA synthesis platform — miniaturizing the chemistry onto chips to produce genes at a scale and cost traditional methods can't touch.
5
The Lore
Its customers span pharmaceuticals, agriculture, and data storage — yes, data storage, because some researchers are literally encoding information into DNA molecules.
6
The Giveaway
This company's name is a nod to the double helix's twist, and its core product is synthetic DNA — genes made to order, by the billions of bases, on demand.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$110.7M

Net Income

Q2 2026

$-44.0M

Free Cash Flow

Q2 2026

$-25.4M

Operating Margin

Q2 2026

-41.4%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+20.3% YoY

$376.6MFY 2025

FY20 $90.1MFY21 $132.3MFY24 $313.0MFY25 $376.6M

Net Income

+62.8% YoY

$-77.7MFY 2025

FY20 $-139.9MFY21 $-152.1MFY24 $-208.7MFY25 $-77.7M

Operating Income

+38.3% YoY

$-136.3MFY 2025

FY20 $-140.1MFY21 $-152.7MFY24 $-220.8MFY25 $-136.3M

EPS (Diluted)

+63.9% YoY

$-1.30FY 2025

FY20 $-3.57FY21 $-3.15FY24 $-3.60FY25 $-1.30

Total Assets

+4.5% YoY

$641.9MFY 2025

FY20 $398.9MFY21 $702.1MFY24 $614.3MFY25 $641.9M

Total Debt

—FY 2025

FY20 $7.5MFY21 $1.6MFY24 —FY25 —

Op. Cash Flow

+25.7% YoY

$-47.6MFY 2025

FY20 $-142.3MFY21 $-112.2MFY24 $-64.1MFY25 $-47.6M

Metric	FY 2025	FY 2024	FY 2021	FY 2020	FY 2018	FY 2017
Revenue	$376.6M +20.3%	$313.0M +136.5%	$132.3M +46.9%	$90.1M +254.3%	$25.4M +136.2%	$10.8M
Net Income	$-77.7M +62.8%	$-208.7M -37.2%	$-152.1M -8.7%	$-139.9M -96.4%	$-71.2M -20.1%	$-59.3M
Operating Income	$-136.3M +38.3%	$-220.8M -44.6%	$-152.7M -9.0%	$-140.1M -98.5%	$-70.6M -20.7%	$-58.5M
EPS (Diluted)	$-1.30 +63.9%	$-3.60 -14.3%	$-3.15 +11.8%	$-3.57	—	—
Total Assets	$641.9M +4.5%	$614.3M -12.5%	$702.1M +76.0%	$398.9M +244.5%	$115.8M	—
Total Debt	—	—	$1.6M -79.3%	$7.5M -22.8%	$9.7M	—
Operating Cash Flow	$-47.6M +25.7%	$-64.1M +42.9%	$-112.2M +21.1%	$-142.3M -115.0%	$-66.2M -29.0%	$-51.3M

AI Insight: TWST Financial Trends

Twist is growing revenue steadily but remains unprofitable with deteriorating operating cash flow despite a brief Q2 2025 net income inflection.

• Revenue grew 37% from Q2 2024 ($81M) to Q1 2026 ($111M), demonstrating consistent growth across the trend.

• Operating margin remains deeply negative, ranging from -39% to -48%, with Q1 2026 at -41%.

• Operating cash flow deteriorated sharply from -$1M in Q2 2025 to -$25M in Q4 2025 and -$18M in Q1 2026.

⚠ Q2 2025 net income of $20M was an outlier; profitability reversed to -$44M loss in Q1 2026, signaling unsustainability.

⚠ Equity eroded from $491M in Q2 2024 to $455M in Q1 2026 despite no debt disclosure; cumulative losses mounting.

AI Insight: TWST Ratio Trends

Twist remains deeply unprofitable with deteriorating Q1 2026 metrics; operating margin worsened to -41.4% after stabilizing near -30% through 2025.

• Operating margin contracted from -31.7% in Q4 2025 to -41.4% in Q1 2026, reversing nine-quarter stabilization trend.

• ROIC dropped to -40.3% in Q1 2026 from -28.8% in Q4 2025, worst reading since Q1 2025's -37.8%.

• Q2 2025 showed brief profitability (NPM +21.2%, ROE +17.1%) but reverted to losses; company has never sustained positive operating margins.

⚠ Q1 2026 deterioration mirrors Q1 2025 pattern; seasonal weakness or structural headwind requires clarification.

⚠ Negative ROIC throughout 2024–2026 signals value destruction; turnaround requires sustained revenue growth and margin expansion.

Get alerted when TWST's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Twist Bioscience Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TWST

Artisan Partners Limited Partnership
$302.6M6,367,777 sh
ARK Investment Management LLC
$301.4M6,342,733 sh
BlackRock, Inc.
$263.9M5,554,362 sh
EdgePoint Investment Group Inc.
$255.8M5,382,521 sh
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC
$250.4M5,269,718 sh
STATE STREET CORP
$174.4M3,670,682 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$125.9M2,649,101 sh
VANGUARD CAPITAL MANAGEMENT LLC
$125.4M2,639,044 sh
Invesco Ltd.
$103.2M2,171,898 sh
FMR LLC
$89.8M1,889,945 sh

Fund	Value	Shares
Artisan Partners Limited Partnership	$302.6M	6,367,777
ARK Investment Management LLC	$301.4M	6,342,733
BlackRock, Inc.	$263.9M	5,554,362
EdgePoint Investment Group Inc.	$255.8M	5,382,521
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC	$250.4M	5,269,718
STATE STREET CORP	$174.4M	3,670,682
VANGUARD PORTFOLIO MANAGEMENT LLC	$125.9M	2,649,101
VANGUARD CAPITAL MANAGEMENT LLC	$125.4M	2,639,044
Invesco Ltd.	$103.2M	2,171,898
FMR LLC	$89.8M	1,889,945

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TWST on your watchlist

Track score changes the day Twist Bioscience Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TWST a good stock to buy?

13F Pro's AI-powered analysis of Twist Bioscience Corp (TWST) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TWST are available on the TWST stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own TWST?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TWST. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Twist Bioscience Corp's investment landscape.